Literature DB >> 8636679

Nosocomial infection in the community hospital: severe infection due to Serratia species.

R I Haddy1, B L Mann, D D Nadkarni, R F Cruz, D J Elshoff, F C Buendia, T A Domers, A M Oberheu.   

Abstract

BACKGROUND: Serratia bacteremia is an uncommon illness in hospitalized patients. The aim of this study was to determine how frequently this disease occurs nosocomially and to discover the most common portals of entry and the underlying disorders.
METHODS: Fifty-six cases of Serratia bacteremia documented by blood culture (17 cases over a 4-year period in a community hospital in Gainesville, Florida, and 39 cases over a 3-year period in three community hospitals in Dayton, Ohio) were reviewed. Comparison was made with 60 control cases of general bacteremia from three Dayton hospitals.
RESULTS: Of the 56 study cases of Serratia bacteremia, 45 (80.4%) were classified as nosocomial, compared with 13 (21.7%) of the controls. Twenty-seven (48.2%) of the 56 Serratia cases occurred in intensive care units. The cases were evenly distributed over the two study periods, and no outbreaks on specific units were noted. The most common portals of entry for Serratia organisms were, in descending order, lung, genitourinary tract, unknown, intravenous line, gastrointestinal tract, and skin. The most common underlying disorder for Serratia bacteremia was malignancy, followed by renal failure (acute or chronic) and diabetes mellitus. Most of the Serratia organisms tested were sensitive to carbenicillin, trimethoprim/sulfamethoxazole, ceftizoxime, ceftriaxone, ceftazidime, cefotetan, aztreonam, ticarcillin/clavulanate, and ciprofloxacin. The organisms were largely resistant to ampicillin, tetracycline, cefazolin, cephalothin, and cefuroxime. Twenty-five percent of the patients with Serratia bacteremia died, compared with 13.6 of the bacteremic controls.
CONCLUSION: Serratia bacteremia is often acquired nosocomially. The mortality rate among the study population was surprisingly low for this opportunistic bacteremia, but was higher (though not significantly so) than that of the controls.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636679

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  13 in total

1.  Serratia sp. bacteremia in Canberra, Australia: a population-based study over 10 years.

Authors:  H J Engel; P J Collignon; P T Whiting; K J Kennedy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-05       Impact factor: 3.267

2.  Virulence factors of the human opportunistic pathogen Serratia marcescens identified by in vivo screening.

Authors:  C Léopold Kurz; Sophie Chauvet; Emmanuel Andrès; Marianne Aurouze; Isabelle Vallet; Gérard P F Michel; Mitch Uh; Jean Celli; Alain Filloux; Sophie De Bentzmann; Ivo Steinmetz; Jules A Hoffmann; B Brett Finlay; Jean-Pierre Gorvel; Dominique Ferrandon; Jonathan J Ewbank
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

3.  Novel tetracycline resistance determinant isolated from an environmental strain of Serratia marcescens.

Authors:  Stuart A Thompson; Elizabeth V Maani; Angela H Lindell; Catherine J King; J Vaun McArthur
Journal:  Appl Environ Microbiol       Date:  2007-02-16       Impact factor: 4.792

4.  Characterization of a cytotoxic factor in culture filtrates of Serratia marcescens.

Authors:  Kent B Marty; Christopher L Williams; Linda J Guynn; Michael J Benedik; Steven R Blanke
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  Fatal Serratia marcescens meningitis and myocarditis in a patient with an indwelling urinary catheter.

Authors:  J S Johnson; J Croall; J S Power; G R Armstrong
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

6.  Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region.

Authors:  K B Laupland; M D Parkins; D B Gregson; D L Church; T Ross; J D D Pitout
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-25       Impact factor: 3.267

7.  Phenotypic diversification and adaptation of Serratia marcescens MG1 biofilm-derived morphotypes.

Authors:  Kai Shyang Koh; Kin Wai Lam; Morten Alhede; Shu Yeong Queck; Maurizio Labbate; Staffan Kjelleberg; Scott A Rice
Journal:  J Bacteriol       Date:  2006-10-27       Impact factor: 3.490

8.  Serratia pneumonia presenting as hemoptysis in a patient with sarcoidosis: a case report.

Authors:  Paul Zarogoulidis; Konstantinos Porpodis; Maria Konoglou; Maria Saroglou; Alexandros Mitrakas; Dimitrios Matthaios; Panagiotis Touzopoulos; Konstantinos Archontogeorgis; Andrew Koulelidis; Konstantinos Zarogoulidis; Stavros Tryfon
Journal:  Int J Gen Med       Date:  2011-09-08

9.  Pathogenicity of Isolates of Serratia Marcescens towards Larvae of the Scarab Phyllophaga Blanchardi (Coleoptera).

Authors:  Mónica L Pineda-Castellanos; Zitlhally Rodríguez-Segura; Francisco J Villalobos; Luciano Hernández; Laura Lina; M Eugenia Nuñez-Valdez
Journal:  Pathogens       Date:  2015-05-13

10.  Serratia marcescens Peritonitis in a Diabetic Patient Receiving Continuous Ambulatory Peritoneal Dialysis.

Authors:  Ji Hyoun Kang; Min Jee Kim; Yong Un Kang; Chang Seong Kim; Joon Seok Choi; Eun Hui Bae; Seong Kwon Ma; Soo Wan Kim
Journal:  Infect Chemother       Date:  2013-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.